MX2021009051A - Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular. - Google Patents

Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular.

Info

Publication number
MX2021009051A
MX2021009051A MX2021009051A MX2021009051A MX2021009051A MX 2021009051 A MX2021009051 A MX 2021009051A MX 2021009051 A MX2021009051 A MX 2021009051A MX 2021009051 A MX2021009051 A MX 2021009051A MX 2021009051 A MX2021009051 A MX 2021009051A
Authority
MX
Mexico
Prior art keywords
pruritus
treatment
patients
skin lesions
prurigo nodularis
Prior art date
Application number
MX2021009051A
Other languages
English (en)
Inventor
Christophe Piketty
Original Assignee
Galderma Holding SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Holding SA filed Critical Galderma Holding SA
Publication of MX2021009051A publication Critical patent/MX2021009051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Abstract

En la presente se describen métodos para tratar selectivamente el prurito en un sujeto que tiene prurigo crónico (CP), que incluye prurigo nodular (PN), composición farmacéuticas para usar en el tratamiento de prurito en un sujeto que tiene CP o PN, usos de nemolizumab o un equivalente de este en la fabricación de un medicamento para el tratamiento de prurito en un sujeto que tiene CP o PN.
MX2021009051A 2019-01-28 2020-01-28 Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular. MX2021009051A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962797803P 2019-01-28 2019-01-28
US201962809404P 2019-02-22 2019-02-22
PCT/IB2020/050623 WO2020157636A1 (en) 2019-01-28 2020-01-28 Treatment of skin lesions and pruritus in prurigo nodularis patients

Publications (1)

Publication Number Publication Date
MX2021009051A true MX2021009051A (es) 2021-12-10

Family

ID=69467604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009051A MX2021009051A (es) 2019-01-28 2020-01-28 Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular.

Country Status (14)

Country Link
US (2) US11236157B2 (es)
EP (1) EP3917617A1 (es)
JP (4) JP7410852B2 (es)
KR (1) KR20210122286A (es)
CN (1) CN113660981A (es)
AU (1) AU2020213978A1 (es)
BR (1) BR112021014854A2 (es)
CA (1) CA3127983A1 (es)
CL (1) CL2021001976A1 (es)
IL (1) IL285171A (es)
MX (1) MX2021009051A (es)
SG (1) SG11202108220YA (es)
TW (1) TW202043282A (es)
WO (1) WO2020157636A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4229084A1 (en) * 2020-10-15 2023-08-23 Intervet International B.V. Caninized rat antibodies to canine interleukin-31 receptor alpha
US20220411518A1 (en) * 2021-04-07 2022-12-29 Galderma Holding S.A. Treatments for prurigo nodularis
CA3230946A1 (en) * 2021-09-15 2023-03-23 Renata Gontijo LIMA Il-13 inhibitors for the treatment of prurigo nodularis
WO2024047497A1 (en) * 2022-09-02 2024-03-07 Galderma Holding SA Treatments for prurigo nodularis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
US20120220948A1 (en) 2008-04-18 2012-08-30 Ipsyrng Capital Development, Llc Ergonomic syringe
DE102007056240A1 (de) 2007-11-22 2009-05-28 Henke-Sass, Wolf Gmbh Spritze
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
NZ773712A (en) 2015-08-24 2023-03-31 Adamis Pharmaceuticals Corp Syringe devices
KR101900427B1 (ko) 2018-05-25 2018-09-20 송향숙 가압력 측정이 가능한 주사기용 보조그립

Also Published As

Publication number Publication date
TW202043282A (zh) 2020-12-01
CN113660981A (zh) 2021-11-16
CA3127983A1 (en) 2020-08-06
BR112021014854A2 (pt) 2021-12-21
US20200239563A1 (en) 2020-07-30
AU2020213978A1 (en) 2021-09-23
JP7375252B2 (ja) 2023-11-07
IL285171A (en) 2021-09-30
WO2020157636A1 (en) 2020-08-06
JP2021509103A (ja) 2021-03-18
JP2022028788A (ja) 2022-02-16
JP2023182834A (ja) 2023-12-26
JP2023126909A (ja) 2023-09-12
JP7309816B2 (ja) 2023-07-18
JP7410852B2 (ja) 2024-01-10
SG11202108220YA (en) 2021-08-30
EP3917617A1 (en) 2021-12-08
CL2021001976A1 (es) 2022-02-11
US11236157B2 (en) 2022-02-01
US20220177568A1 (en) 2022-06-09
KR20210122286A (ko) 2021-10-08

Similar Documents

Publication Publication Date Title
MX2021009051A (es) Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular.
MX2020009773A (es) Terapia de combinacion.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2019003134A (es) Terapia de combinacion.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
PH12020551038A1 (en) Compositions comprising co-selected microbiota and methods for use thereof
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
WO2020186132A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MX2020001727A (es) Terapia de combinacion.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
JOP20220168A1 (ar) طرق علاج الطحال
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
CY1125075T1 (el) Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2022001266A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.